| HOME >> MEDICINE >> TECHNOLOGY |
December 31, 2011, respectively
——Common stock—par value $0.001; Authorized shares: 300,000,000,
issued and outstanding: 144,313,005 at December 31, 2012 and
134,968,394 at December 31, 2011
144,313134,968Additional paid-in capital
263,897,116257,235,707Accumulated deficit
(229,760,129)(210,091,174)Accumulated other comprehensive income
73,36235,393Total Inovio Pharmaceuticals, Inc. stockholders' equity34,354,66247,314,894Non-controlling interest
502,743546,768Total stockholders' equity
34,857,40547,861,662Total liabilities and stockholders' equity$
45,138,754$
61,106,561
Inovio Pharmaceuticals, Inc.CONSOLIDATED STATEMENTS OF OPERATIONSFor the Years ended December 31,201220112010Revenues:License fee and milestone revenue
$
82,536$
156,397$
213,916License fee and milestone revenue from affiliated entity
425,000411,459313,306Revenue under collaborative research and development
arrangements with affiliated entity
152,467——Grants and miscellaneous revenue
3,458,6499,227,4015,549,583Miscellaneous revenue from affiliated entity
——67,900Total revenues4,118,6529,795,2576,144,705Operating expenses:Research and development
17,984,82520,032,00113,256,606General and administrative
10,778,35911,988,79612,108,261Gain on sale of assets
(1,151,000)(587,000)—Total operating expenses27,612,18431,433,79725,364,867Loss from operations(23,493,532)(21,638,540)(19,220,162)Other income (expense):Interest and other income, net
166,11334,285147,406Change in fair value of common stock warrants
1,982,6208,690,6582,403,924Gain (Loss) on investment in affiliated entity
1,631,819(2,390,498)(969,914)Net loss(19,712,980)(15,304,095)(17,638,746)Net loss at
'/>"/>
| SOURCE Inovio Pharmaceuticals, Inc. Copyright©2012 PR Newswire. All rights reserved |